We would love to hear your thoughts about our site and services, please take our survey here.
Every shareholder knew before investing the powerful position that GC and a few friends held in Tiziana, therefore voting against the corporate reorganisation would be both futile and counter productive. I also think that most large investors will
vote in favour to protect both their interests and pockets to avoid a total catastrophe.
It's important to remember the track record of GC in this sector which WAS previously highly successful, he has assembled a very experienced and powerful scientific team around him which are (age wise) in the "twilight" of their career's with the possibility of a very rewarding conclusion in mind.
The corporate performance of GC over the last 12 months has been been damaging /inept and disgraceful, this has been further compounded with a totally ill thought out / advised blundering strategy which would struggle to get into a publication of " Idiots guild to " My conclusion to this is that GC has selfishly taken his eye off the scientific ball to concentrate on both his personal and corporate tax efficient planning, this could also be viewed / seen as a good indicator to our future potential financial rewards.
However painful it is now for us "irrelevant" at massive losses private investors, the move to Nasdaq listing only, for both Tiziana and AccuStem will eventually reverse our losses and reward the faith we have in our science.
USA / Nasdaq is the best platform for the future and the Share Capital Consolidation reducing the number of shares available is also a positive move.
A yes vote, News and a few positive days on the Nasdaq could be great boost to our current situation
If the BOD can earn and restore lost sentiment we may have a chance of recovery
GLA
DYOR ( not available for badly planned corporate actions unfortunately )
20th January 2021, 19,7m shares traded
Closing price on the 19th was $3.17
Closing price on the 20th was $4.73 ( day high was $5.29 )
Nasdaq is the optimum future for Tiziana
Reply from HL regarding Accustem shares held in ISA's
Thank you for your message. At present, the shares are unlisted and under HMRC rules must be moved out the ISA within 30 days. However, as the shares are due to be listed on the NASDAQ this could be an exception to the rule and be classified as a intermediate investment. Unfortunately, this does not allow for an extension to the 30 day period but we have enquired with HMRC about whether this would class as an exception and then we will contact shareholders again once we receive an update.
Please let me know if you have any further questions.
Many of Tiziana decisions ( or lack of ) over the last six months have been rather frustrating or infuriating but the rationale behind yesterdays RNS was summarized quite well in this article.
One of the golden rules of the tech and biotech space is that like for like, if UK companies happened to be listed on the U.S. market you could normally add a zero to the market cap. This is in addition to much greater liquidity. Such an observation may have been the rather obvious driver for the latest announcement from Tiziana Life Sciences (TILS), which one day last summer saw its U.S. equivalent listing rub shoulders with Microsoft and Tesla in terms of trading volume. The company said that following a review it has been concluded that shareholders are best served by a direct listing on NASDAQ. Given this intention, the Board concluded that England was not the most appropriate domicile for the parent company of the Tiziana Group because it is not possible to directly list shares of English companies on NASDAQ.
For most investors here suffering heavy losses its a crumb of comfort and a glimpse of what could await us in the future, small consolation I know at present, but maybe light at the end of this dark tunnel eventually
Patience is a very easy word to say and type but sometimes very difficult to endure
Best wishes Roker, I will miss your balanced informative posts.
Nasdaq will be a very good move for us in the future "hopefully". GC is no fool I keep telling myself, even though I have a love / "hate" relationship with him.
Hopefully see you back here in the future
LJ, Just to clarify
2 x TSLA purchased (Entitled ) Accustem shares equals 1 x Accustem ADR
1 x Tils purchased (Entitled ) Accustem share equals 1 x Accustem ADR
This is exactly the same ratio that Tils / TLSA are currently trading at
The price that the OTC market is currently trading at is for 1 x Accustem ADR
Therefore the price for our Tils purchased (Entitled) Accustem share is 1 x Accustem ADR which is currently say 50c
50 cents converted to Sterling would be +/- 36p
Owning over 400k Accustem shares myself, if these ratio's where any different to the detriment of UK Accustem shareholders I'm pretty sure legal action would be taken against the company
Wisha, I think your calculation of 16p is incorrect it should be double that
I x Tils purchased (Entitled) Accustem share equals 1 x Accustem ADR (not 1 x Accustem share)
This would be exactly the same ratio used in the Tils / TLSA shares purchased, that qualified us for the Accustem entitlement) .
Alternatively if incorrect we would have been royally SCREWED by paying double what the USA paid for their entitlement
Hi Bluebelly, I think this is the document your referring to https://ir.tizianalifesciences.com/node/9201/html
We may offer, issue and sell from time to time up to $250,000,000, or its equivalent in any other currency, currency units, or composite currency or currencies, of our ordinary shares, in the form of American Depositary Shares, or ADSs, warrants to purchase ordinary shares, in the form of ADSs and a combination of such securities, separately or as units, in one or more offerings. Each ADS represents 2 ordinary shares. This prospectus provides a general description of offerings of these securities that we may undertake.
We refer to our ADSs, ordinary shares, warrants, and units collectively as “securities” in this prospectus.
Each time we sell our securities pursuant to this prospectus, we will provide the specific terms of such offering in a supplement to this prospectus. The prospectus supplement may also add, update, or change information contained in this prospectus. You should read this prospectus, the accompanying prospectus supplement, together with the additional information described under the heading “Where You Can Find More Information,” before you make your investment decision.
We may, from time to time, offer to sell the securities, through public or private transactions, directly or through underwriters, agents or dealers, on or off The Nasdaq Global Market, at prevailing market prices or at privately negotiated prices. If any underwriters, agents or dealers are involved in the sale of any of these securities, the applicable prospectus supplement will set forth the names of the underwriter, agent or dealer and any applicable fees, commissions or discounts.
Our ADSs issued in connection with our November 2018 initial public offering in the United States are listed on The Nasdaq Global Market under the symbol “TLSA”. On January 25, 2021, the last reported price of our ADSs on The Nasdaq Global Market was $3.71 per ADS.
Our ordinary shares are admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority, or the FCA, and to trading on the main market for listed securities, or Main Market, of London Stock Exchange plc, or the London Stock Exchange, under the symbol “TILS.” On January 25, 2021, the last reported price of our ordinary shares was £1.50 per share (equivalent to $4.11 per ADS based on an exchange rate of £1.00 to $1.3685).
We are an “emerging growth company,” as defined by the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings.
Investing in our securities involves a high degree of risk. Please carefully consider the risks discussed in this prospectus under “Risk Factors” in this prospectus, in any accompanying prospectus supplement and in the documents incorporated by reference i
Hi Roker, very glad to see you investing more in Tils again, I always feel easier reading your balanced comments. wow you certainly brought some venom out.
jh2704, Being critiical of the BOD is perfectly fine if they DESERVE IT, Lots of things to be critical about their recent performances. Keep your rose tinted glasses on and your attacks to yourself.
Like I said to Roker recently GC is a genius entrepreneur but an arrogant SOB. we knew about his power in the company so have to accept his blaise sloppy way of operating a listed company
Sanijuelas1, why don't you go play with another share ?. Nobody wants to waste time reading your vengeful, vindictive posts.
You appear to be a relatively intelligent person why not spend your time elsewhere and be appreciated. Please
MIKODX, Rokerpark has forgotten more about shares than you will probably ever know.
"The company has been very generous by giving investors free shares in the company"
We didn't get FREE SHARES it was an asset that was part of our Tils share purchase, NOT FREE Comprende ?
"I wouldn't put down this company for one second even if I felt the demerger wasn't handled well, which I actually think it was."
This demerger could go down in history for being one of the worst "structured /planned / delayed" process of all time
"I've jumped in and out of this stock multiple times and have made very decent gains"
Lol what a loyal shareholder you are, speculative trader would be more appropriate, ramp up till your next sell off.
I say this being one of the largest non selling LTH PI investors in Tils, I don't like being critical of a share I'm heavily invested in but the BOD have been very poor in many aspects.
Anyway glad to see Rokerpark still posting and BB for previous comments
Bluebelly, agree with your comment regarding the BOD
Hi Roker, Good balanced post as usual, I have a love / "hate" opinion of GC. He has a very good track record for an entrepreneur which excites me and was one of the reasons why I invested. However no amount of research will ever be available to foreworn investors from his Jekyll & Hyde sloppy relaxed approach to corporate management.
I have a moan occasionally because of this frustration but despite a 50% loss still believe that the science will eventually provide a positive outcome. We all knew his dominant shareholding and power before investing and like you stated warts and all must be "accepted".
Apologies for the previous post, I missed the introduction and presumed it was a Tiziana representative. The remainder of the post is unchanged.
Plan2Retire. I don't bash a share that I'm very heavily invested in without good reason, you should maybe change those rose tinted glasses and take note of other investors concerns . The science is and will be the only saviour of this company and not the current / recent unprofessional corporate management performance.
Tiziana have a brilliant charismatic person in the good doctor who SHOULD be doing this Interview, what does the company do ? send a rank dour, fumbling replacement that does absolutely nothing to stir up interest.
Are they doing this on purpose or do the push the self destruction button automatically ?
Agree with the Accustem trading on Nasdaq only but without question the worst unprofessional demerger process ever
undertaken.
Even more frustrated with this share now. another day another drop being the usual pattern
Nasdaq listing only is also my interpretation, communication from this company always leaves a lot to be desired, WHY ?
26th October Last day to purchase shares that qualified (2 days settlement) to receive Accustem the closing price was £1.84
2nd November the opening price was £ 1.43 pre Covid related Vaccine "crash" so Tiziana dropped +/- 41p "directly" linked to the demerger at the time.
BM3, Hope you and the family are ok, I did say that I hoped the recipient benefits, it's impossible to evaluate on just one person good or bad was my concern.
Oldapache, My post, my opinion. my investment (currently 40% down) so I will select when to sell. you have taken your action so carry on LTH trading
Yesterday's news was ZERO news, surprise surprise where the share price is going again.
1st RNS confirmed what we already knew in January
2nd RNS confirmed that the 2nd quarterly quoted deadline has been missed again
3rd RNS was just throwing a FDA "sensational" headline which will have zero relevance being just 1 person good or bad. I sincerely hope the recipient benefits from the treatment
Bloomberg interview was a waste of time with absolutely Zero new revelations. (A.P.B. has now been withdrawn on GC)
Summary is, Radio silence broken by what exactly ? ZERO news that really just irritates investors being treated like idiots
Frustrated large non trading LTH who has only seen a blue figure for a few hours on this "investment"
Brilliant scientific pipeline needs professional management to realise the vast potential otherwise many will follow the route of Empery / Altium
Oldapache, Your constant moaning at "whingers" is also getting quite irritating. Unlike you who have got in at the bottom and traded / top sliced and constantly profit taken resulting in probably trading with "free shares", little wonder you don't care about the awful share price.
Investors who started around the same time as the placing of 57m @ £2 (described on here as "suckers",who have since cut losses and sold shares at multi million losses) have yet to see a blue figure, or a break even on investment in 6 months ( excluding a few HOURS on a 2 spikes ) so it's hardly surprising that people complain.
If its not the LTH traders and profit takers taking the share price down its the BOD actions and lack of communication with shareholders. I also find it very strange the the usual rampers who broadcast "top ups" at these "bargain prices" have all disappeared ? Where are all the lost investors ? Where are all the new investors coming from ? Very concerning time for this share, so no need to be chasing the current investors away.
Maybe consideration for others could be a possibility in future ?